All News

2022,wordle

2022 Rheumatology Year in Review

Jack Cush, MD

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article
RheumNow Podcast square

Best of 2022: EULAR 2022 Top 10 Abstracts

Jack Cush, MD

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media…

Read Article
RheumNow Podcast square

Fever, FROST, & Pericarditis (12.16.2022)

Jack Cush, MD

Dr. Jack Frost reviews the news, and journal articles from the past week on RheumNow and ends with an audience question on "Macro-CK".

Read Article
hidradenitis.jpg

Inflammatory Arthritis and Hidradenitis Suppurativa

Jack Cush, MD

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by

Read Article
cost.price_.biologic.injectable.jpg

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Jack Cush, MD

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.

Read Article
ACR meeting education

ACR22 Takeaways: Pre-RA, Lupus, PsA and AS

Robert Chao, MD

ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways. 

Read Article
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered. RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually! https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd

Links:

Dr. John Cush RheumNow ( View Tweet)
There is considerable overlap between fibromyalgia tender points and an enthesitis score in axial spondyloarthritis pts. 526 pts in the Predict-SpA study (53% men, 38% FM) assessed 18 TP and 13 Entheses found ICC between both scores of 0.7 https://t.co/ESmP26plDB https://t.co/7X1XhyML0f

Links:

Dr. John Cush RheumNow ( View Tweet)
Many have quoted and shown this image of Ankylosing Spondylitis in a young military recruit at age 25, 35, 45, 50 & 51yrs. This may be the MOST used slide in rheum! It comes from the work of Toronto's Dr. Hugh Little, who sadly passed away at age 58 yrs. https… https://t.co/G28YlyhX3v
Dr. John Cush RheumNow ( View Tweet)
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/hjXEopji6r https://t.co/FwzBa2YNzb

Links:

Dr. John Cush RheumNow ( View Tweet)
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/Kc1n4RVe3v

Links:

Dr. John Cush RheumNow ( View Tweet)

The First Head to Head trial in Axial SpA Dr.Gensler discusses abstract L15 presented at #ACR22. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic AxSpA: A Randomized Phase IIIb Study https://t.co/J0DT1yw0vQ https://t.co/kKhFQKAy6H

Links:

Dr. John Cush RheumNow ( View Tweet)
Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. https://t.co/dCLlgiGV9K https://t.co/a4iI1q3zZC

Links:

Dr. John Cush RheumNow ( View Tweet)
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease. https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Dr. Lianne Gensler ( @lianegensler discusses the following abstracts presented at #ACR22. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes) https://t.co/f7o8UARKNl https://t.co/ryVmD86UoI

Links:

Dr. John Cush RheumNow ( View Tweet)
A Multidimensional Approach in the Management of Axial Spondylarthritis Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis. https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo

Links:

Dr. John Cush RheumNow ( View Tweet)
Lifestyle Modifications may enhance TNF Inhibitors in axSpA https://t.co/0O4jd3g0WL https://t.co/zUaRUR9tGL

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too! https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Topic Panel - #ACR22 SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims @synovialjoints @AkhilSoodMD @ericdeinmd @RHEUMarampa @DrCassySims https://t.co/uFPW3NxZEm https://t.co/stjmhcFoaS

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA from #ACR22. -Abstract 0402 -Abstract 0388 -Abstract 0544 -Abstract 0545 https://t.co/1PvN3SnqHQ https://t.co/i2nyvjyv3D

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×